Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2R86O)

Drug Name
Siponimod Drug Info
Synonyms BAF312
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Cross-matching ID
PubChem CID
44599207
CAS Number
CAS 1230487-00-9
TTD Drug ID
DM2R86O
VARIDT Drug ID
DR00743
INTEDE Drug ID
DR1488
ACDINA Drug ID
D01430

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1 phosphate receptor (S1PR) TT7BQRM NOUNIPROTAC Modulator [1]
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [4]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Approved [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Sphingosine-1-phosphate receptor 1 (S1PR1) DTT S1PR1 6.829 6.89 6.853 5.959
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 08 Nervous system disease
Disease Class ICD-11: 8A40 Multiple sclerosis
The Studied Tissue Plasmacytoid dendritic cells
The Studied Disease Multiple sclerosis [ICD-11:8A40]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.09E-01 -9.26E-02 -3.68E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT01665144) Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.